Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Carbonyl Reductase Mutant. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN111172124B details a YOL151W mutant for high-concentration synthesis, offering cost-effective pharma intermediate manufacturing.
Novel carbonyl reductase mutant enables high-purity chiral intermediate synthesis with reduced solvent waste and cost for pharmaceutical supply chains.
Patent CN112941043B details a carbonyl reductase mutant for synthesizing chiral intermediates. Offers high yield and scalability for carbapenem antibiotic production supply chains.
Patent CN112852768B reveals engineered carbonyl reductase mutants for high-purity chiral nitrile synthesis, offering significant cost reduction in API manufacturing and scalable green chemistry solutions.
Patent CN110387359B discloses engineered enzymes for efficient statin production, offering significant cost reduction and supply chain reliability for pharmaceutical manufacturers.
Patent CN114410599A demonstrates enhanced enzymatic efficiency for rosuvastatin side chains offering substantial cost reduction and supply chain reliability for global pharmaceutical manufacturers.
Novel carbonyl reductase mutants enable high-yield rosuvastatin intermediate production with reduced costs and enhanced supply chain reliability for global pharmaceutical manufacturers.
Patent CN113801859A details high-efficiency carbonyl reductase mutants for chiral alcohol synthesis, offering superior stereoselectivity and cost reduction in pharmaceutical manufacturing.
Patent CN104099305A reveals stable CgKR1 mutants for Clopidogrel intermediates. Enhances purity and supply chain reliability for global pharmaceutical manufacturing.
Patent CN111172124A reveals a novel carbonyl reductase mutant enabling high-concentration synthesis. Discover cost-effective supply chain solutions for this key pharma intermediate.
Patent CN113652408B reveals mutant enzyme for high-purity intermediate. Offers supply chain reliability and cost reduction in pharmaceutical intermediates manufacturing.